Abstract

We assessed the efficacy and safety of recombinant human insulin-like growth factor 1 (IGF-1) therapy over a period of 7.5 years in a child with severe IGF-1 deficiency. Recombinant human IGF-1 was administered subcutaneously in doses between 40 and 80 microg/kg once daily. Height velocity increased from 2 cm/year on average at baseline to 7.9 cm/year during the first year of treatment. In the following years, growth velocity was less but satisfactory during treatment, but decreased when therapy was stopped.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call